Comparative effect of pioglitazone, quercetin and hydroxy citric acid on the status of lipid peroxidation and antioxidants in experimental non-alcoholic steatohepatitis

Journal of Physiology and Pharmacology

Volumn 65, Issue 1, 2014, Pages 67-74

  Surapaneni, Krishna Mohan ^a   Jainu, M ^b  

^a SAVEETHA MEDICAL COLLEGE AND HOSPITAL   (India)

^b SSN COLLEGE OF ENGINEERING   (India)

Author keywords

Antioxidants; Hydroxy citric acid; Non alcoholic fatty liver disease; Nonalcoholic steatohepatitis; Oxidative stress; Pioglitazone; Quercetin

Indexed keywords

CATALASE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; HYDROXYCITRIC ACID; MALONALDEHYDE; PIOGLITAZONE; QUERCETIN; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ASSAY; ARTICLE; CONTROLLED STUDY; ENZYMATIC ASSAY; ENZYME ACTIVITY; FAT INTAKE; HISTOPATHOLOGY; LIPID PEROXIDATION; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; QUANTITATIVE ANALYSIS;

ANIMALS; ANTIOXIDANTS; CATALASE; CITRATES; DIET, HIGH-FAT; FATTY LIVER; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; HYPOGLYCEMIC AGENTS; LIPID PEROXIDATION; LIVER; MALE; QUERCETIN; RATS; RATS, WISTAR; SUPEROXIDE DISMUTASE; THIAZOLIDINEDIONES;

EID: 84896899135     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Ahmed MH, Byrne CD. Non-alcoholic steatohepatitis. In: Metabolic Syndrome. C.D. Byrne, S. Wild, (ed). Chichester, John Wiley & Sons, 2005, pp. 279-305.
2. Liou I, Kowdley KV. Natural history of non-alcoholic steatohepatitis. J Clin Gastroenterol 2006; 40: S11-S16.
3. Farrell GC, Larter CZ. Non-alcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology, 2006; 43 (Suppl. 1): S99-S112.
4. Pascale A, Pais R, Ratziu V. An overview of non-alcoholic steatohepatitis: past, present and future directions. J Gastrointestin Liver Dis 2010; 19: 415-423.
5. Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH. Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci (London) 2009; 116: 539-564.
6. Wei Y, Clark SE, Thyfault JP, et al. Oxidative stressmediated mitochondrial dysfunction contributes to angiotensin II-induced non-alcoholic fatty liver disease in transgenic Ren2 rats. Am J Pathol 2009; 175: 2709-2710.
7. Edmison J, McCullough AJ. Pathogenesis of non-alcoholic steatohepatitis: human data. Clin Liver Dis 2007; 11: 75-104.
8. Song SC, Choi SH, Choi DW, Heo JS, Kim WS, Kim JM. Potential risk factors for non-alcoholic steatohepatitis related to pancreatic secretions following pancreaticoduodenectomy. World J Gastroenterol 2011; 17: 3716-3723.
9. London RM, George J. Pathogenesis of NASH: animal models. Clin Liver Dis 2007; 11: 55-74.
10. Arthur J. McCullough. Pathophysiology of non-alcoholic steatohepatitis. J Clin Gastroenterol 2006; 40: S17-S29.
11. Grigorescu M, Crisan D, Radu C, Grigorescu MD, Sparchez Z, Serban A. A novel pathophysiological-based panel of biomarkers for the diagnosis of non-alcoholic steatohepatitis. J Physiol Pharmacol 2012; 63: 347-353.
12. Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 2006; 6: 1-28.
13. Arendt B, Allard J. Effect of atorvastatin, vitamin E and C on non-alcoholic fatty liver disease is the combination required? Am J Gastroenterol 2011; 106: 78-80.
14. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for non-alcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-1685.
15. Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of non-alcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011; 305: 1659-1668.
16. Surapaneni KM, Saraswathi P, Jainu M. non-alcoholic steatohepatitis (NASH) experimental model induction in rats. Int J Pharm Bio Sci 2012; 3: 1085-1090.
17. Rivera L, Moron R, Sanchez M, Zarzuelo A, Galisteo M. Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese zucker rats. Obesity 2008; 16: 2081-2087.
18. Surapaneni KM, Sarswathi P, Jainu M. Role of pioglitazone, quercetin and hydroxy citric acid against non-alcoholic steatohepatitis (NASH)-histological and scanning electron microscopy (SEM) studies in an experimental model of NASH. Asian J Pharm Clin Res 2012; 5: 244-247.
19. Surapaneni KM, Jainu M. Effect of pioglitazone, quercetin, and hydroxy citric acid on the lipid profile and lipoproteins in experimentally induced non-alcoholic steatohepatitis (NASH). Indian J Pharm Educ Res 2014; 48: 32-38.
20. Okhawa H, Ohishi N, Yagi K. Assay for lipid peroxide in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95; 351-357.
21. Moron NS, Depierre JW, Mannervik B. Levels of glutathione, glutathione reductase and glutathione-Stransferase activities in rat lung and liver. Biochem Biophys Acta 1979; 582: 67-72.
22. Sinha AK. Colorimetric assay of catalase. Anal Biochem 1972; 47: 389-394.
23. Misra HP, Fridovich I. The role of superoxide anion in the autooxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 1972; 247: 3170-3175.
24. Rotruck JT, Pope AL, Ganther H, Awanson AB, Hafeman DG, Hoeckstra WG. Selenium biochemical role as a component of glutathione peroxidase. Science 1973; 179: 588-590.
25. Carlberg I, Mannervik B. Purification and characterization of the flavoenzyme glutathione reductase from rat liver. J Biol Chem 1975; 250: 5475-480.
26. Habig WH, Pabst MJ, Jakoby WB. Glutathione-Stransferase. The first enzymatic step in mercapturic acid formation. J Biol Chem 1974; 249: 7130-7139.
27. Fierbinteanu-Braticevici C, Negreanu L, Tarantino G. Is fatty liver always benign and should not consequently be treated? J Physiol Pharm 2013; 64: 3-9.
28. Leclerq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine non-alcoholic steatohepatitis. J Clin Invest 2000; 105: 1067-1075.
29. George J, Pera N, Phung N, Leclercq I, Yun Hou J, Farrell G. Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J Hepatol 2003; 39: 756-764.
30. Koruk M, Taysi S, Savas MC, Yilmaz O, Akcay F, Karakok M. Oxidative stress and enzymatic antioxidant status in patients with non-alcoholic steatohepatitis. Ann Clin Lab Sci 2004; 34: 57-62.
31. Lieber CS. Cytochrome P-4502E1: its physiological and pathological role. Physiol Rev 1997; 77: 517-544.
32. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metofrmin in non-alcoholic steatohepatitis. Lancet 2001; 358: 893-894.
33. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-1192.
34. Plaa GL, Witschi H. Chemicals, drugs, and lipid peroxidation. Ann Rev Pharmacol Toxicol 1976; 16: 125-141.
35. Sies H. Oxidative stress: from basic research to clinical application. Am J Med 1991; 9(3C): 31S-38S.
36. Fang YZ, Yang S, Wu G. Free radicals, antioxidants, and nutrition. Nutrition 2002; 18: 872-879.
37. Blokhina O, Virolainen E, Fagerstedt KV. Antioxidants, oxidative damage and oxygen deprivation stress: a review. Ann Bot 2003; 91 (Spec. No): 179-194.
38. Gonciarz M, Gonciarz Z, Bielanski W, et al. The effects of long-term melatonin treatment on plasma liver enzymes levels and plasma concentrations of lipids and melatonin in patients with non-alcoholic steatohepatitis: a pilot study. J Physiol Pharm 2012; 63: 35-40.
39. Paradis V, Mathurin P, Kollinger M, et al. In situ detection of lipid peroxidation in chronic hepatitis C: correlation with pathological features. J Clin Pathol 1997; 50: 401-406.
40. Yadav D, Hertan HI, Schweitzer P, Norkus EP, Pitchumoni CS. Serum and liver micronutrient antioxidants and serum oxidative stress in patients with chronic hepatitis C. Am J Gastroenterol 2002; 97: 2634-2649.
41. DiMascio P, Murphy ME, Sies H. Antioxidant defense systems: the role of the carotenoids, tocopherols and thiols. Am J Clin Nutr 1991; 53 (Suppl.): 194S-200S.
42. Harris ED. Regulation of antioxidant enzymes. FASEB J 1992; 6: 2675-83.
43. Vendeniale G, Grattagliano I, Caraceni P, et al. Mitochondrial oxidative injury and energy metabolism alteration in rat fatty liver: effect of the nutritional status. Hepatology 2001; 33: 808-815.
44. Sreekumar R, Gonzalez-Koch A, Maor-Kendlex Y, et al. Early identification of recipients with progressive histologic recurrence of hepatitis c after liver transplantation. Hepatology 2000; 32: 1125-1130.
45. Irie M, Sohda T, Iwata K, et al. Levels of the oxidative stress marker gamma glutamyltranspeptidase at different stages of non-alcoholic fatty liver disease. J Int Med Res 2012; 40: 924-933.
46. Somi MH, Hajipour B, Asl NA, et al. Pioglitazone attenuates ischemia/reperfusion-induced liver injury in rats. Transplant Proc 2009; 41: 4105-4109.
47. Mishra A, Bapat MA, Tilak JC, Devasagayam TA. Antioxidant activity of Garcinia indica (kokam) and its syrup. Curr Sci 2006; 91: 90-93.
48. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-1192.
49. Sanyal AJ, Mofrad PS, Contos MJ, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of non-alcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004; 2: 1107-1115.
50. Baskol G, Baskol M, Kocer D. Oxidative stress and antioxidant defenses in serum of patients with non-alcoholic steatohepatitis. Clin Biochem 2007; 40: 776-780.
51. Amin KA, Kamel HH, Abd Eltawab MA. The relation of high fat diet, metabolic disturbances and brain oxidative dysfunction: modulation by hydroxy citric acid. Lipids Health Dis 2011; 10: 74. doi: 10.1186/1476-511X-10-74.
52. Choi EJ, Chee EM, Lee BH. Anti-and prooxidant effects of chronic quercetin administration in rats. Eur J Pharmacol 2003; 482: 281-285.
53. Amalia PM, Possa MN, Augusto MC, Francisca LS. Quercetin prevents oxidative stress in cirrhotic rats. Dig Dis Sci 2007; 52: 2616-2621.
54. Kamaraj S, Vinodhkumar R, Anandakumar P, Jagan S, Ramakrishnan G, Devaki T. The effects of quercetin on antioxidant status and tumor markers in the lung and serum of mice treated with benzo(a)pyrene. Biol Pharm Bull 2007; 12: 2268-2273.
55. Padma VV, Lalitha G, Shirony NP, Baskaran R. Effect of quercetin against lindane induced alterations in the serum and hepatic tissue lipids in wistar rats. Asian Pac J Trop Biomed 2012; 2: 910-915.
56. Marcolin E, Forgiarini LF, Rodrigues G, et al. Quercetin decreases liver damage in mice with non-alcoholic steatohepatitis. Basic Clin Pharmacol Toxicol 2013; 112: 385-391.